NCT03406377View on ClinicalTrials.gov

Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

April 2, 2018

Primary Completion Date

March 8, 2019

Study Completion Date

June 27, 2019

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

OPK-88003

OPK-88003 subcutaneous injection

DRUG

Placebo

Placebo subcutaneous injection

Trial Locations (3)

33014

Clinical Pharmacology of Miami, LLC, Hialeah

90057

National Research Institute - Wilshire, Los Angeles

90255

National Research Institute - Huntington Park, Huntington Park

All Listed Sponsors
lead

OPKO Health, Inc.

INDUSTRY

NCT03406377 - Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects | Biotech Hunter | Biotech Hunter